Can a high-protein diet stop GLP-1 muscle loss?

GLP-1 medications like semaglutide and tirzepatide reliably produce large amounts of weight loss, but a meaningful share of that loss is muscle, not fat.2 A new clinical trial registered on ClinicalTrials.gov, named LEAN-PRO GLP-1, is now testing a specific, practical countermeasure: whether simply eating more protein while on a GLP-1 drug preserves meaningfully more muscle than standard dietary advice.1

What is the LEAN-PRO GLP-1 trial actually testing?

The trial's official title is "The Effect of GLP-1 Receptor Agonist-based Treatment on Body Composition and Muscle Mass in Adults With Obesity," registered under identifier NCT07495904.1 It is sponsored by Hellenic Mediterranean University and runs out of two sites in Heraklion, Greece: the University General Hospital of Heraklion and the university's Human Dietetics and Body Composition Laboratory.

Researchers will randomize 130 adults aged 30 to 65 with a body mass index of 30 or above into two parallel groups. Every participant receives GLP-1 receptor agonist treatment - the specific drug is not specified in the public protocol. What differs between the groups is the dietary guidance layered on top of the medication.

Source: ClinicalTrials.gov record NCT07495904.1 Exact protein dosing and the specific GLP-1 drug used are not specified in the public protocol.

How will researchers measure muscle mass?

The primary outcome is change in muscle mass from baseline, tracked over an intervention period of up to 24 weeks.1 Rather than relying on a single method, the study uses a multi-compartment body composition model that combines underwater weighing, dual-energy X-ray absorptiometry (DEXA), and bioelectrical impedance spectroscopy - a more rigorous approach than the single bioimpedance scans used in many smaller studies.

Secondary outcomes include fat mass, fat-free mass, total body protein, hydration status, glucose and lipid markers, sarcopenia risk via the SARC-F questionnaire and handgrip strength, dietary adherence, and weight regain tracked for six months after the intervention ends.1

"There is no result here yet - only a well-designed question. That is worth tracking, not skipping."

Who can join, and who is excluded?

Eligible participants are adults aged 30 to 65 with a BMI of 30 or above who provide signed informed consent.1 The exclusion list is long and clinically conservative: uncontrolled type 2 diabetes (HbA1c above 9.0%), existing cardiovascular disease, chronic kidney disease stage 4 or 5, liver disease, inflammatory bowel disease, celiac disease, a history of pancreatitis, active cancer within the past three years, use of protein or creatine supplements, substance abuse, pregnancy, and intense regular physical activity.

That exclusion list matters for interpreting future results. Whatever this trial finds will most directly apply to relatively healthy adults with obesity and no major comorbidities - not to the full population of people on GLP-1 therapy, many of whom have diabetes or cardiovascular disease.

Why does this question matter?

A 2025 network meta-analysis of 22 randomized controlled trials and 2,258 patients found GLP-1 medications reduce lean muscle mass by roughly 0.86 kg per course - about 24% of total weight lost.2 Losing muscle alongside fat raises long-term concerns about sarcopenic obesity, particularly as GLP-1 use expands among older adults. LEAN-PRO GLP-1 is one of the first randomized trials designed specifically to test a low-cost, accessible countermeasure - dietary protein - rather than a second drug or supplement.

An academic sponsor with no drug or supplement to sell is also a meaningfully different funding profile than most GLP-1 comparative research, much of which is funded by the manufacturers of the drugs being studied.

What this does not mean - yet

This trial has produced no data. It cannot yet be cited as evidence that high-protein diets preserve muscle during GLP-1 treatment - that is the hypothesis being tested, not a finding. Recruitment is ongoing as of June 2026, and results are not expected before the primary completion date of March 30, 2028.

In one sentence: a 130-person Greek trial is testing whether high dietary protein protects muscle mass better than standard counseling during GLP-1 treatment, the trial has no results yet, and its findings - expected no earlier than 2028 - will apply most directly to relatively healthy adults with obesity.